Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials

By E. Vermes, J. Tardif, M. Bourassa, N. Racine, S. Lévesque, M. White, P. Guerra, A. Ducharme. Circulation, 2003

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, background): “A lower incidence of new atrial fibrillation was also observed in three heart failure trials, when the ACE inhibitor, enalapril (379) or the angiotensin receptor antagonists, candesartan (380) and valsartan (381) were compared with placebo as add-on therapy.”
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, result): “Secondary analyses of trials in patients with LVH and hypertension have found that ARBs (losartan, valsartan) are better in preventing first occurrence of atrial fibrillation than beta-blocker (atenolol) or calcium antagonist (amlodipine) therapy, consistent with similar analyses in patients with he”
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. (2005, background): “Our study extends previous reports suggesting that reninangiotensin system blockade by either angiotensinconverting enzyme inhibition (4, 20 ) or angiotensin II receptor blockade (9) reduces incident AF. In the TRACE study new-onset AF was reduced by 45% with trandolapril (4).”